MCI / AD Subtypes

A man performing Alzheimer's disease research

SYNTap Test Capabilities

This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.

Specification Sheet

SYNTap Spec Sheet - Disease Lead

Identifying Lewy body pathology at the MCI stage allows for a more personalized approach to disease management.

Ongoing studies indicate the need for early diagnosis and better definition of AD sub-types.

“Our results support a role for α-synuclein even in MCI, the early phase of AD, in addition to being a potential contributor in MCI and AD diagnosis or monitoring of disease progression.” (Ref.6)

Relevant Research Findings

In a recently published article in Neurology Rossi et al found the following

“RT-QuIC (a research version of SAA) “identified patients with MCI-LB against cognitively unimpaired controls with 95% sensitivity, 97% specificity, and 96% accuracy and showed 98% specificity in neuropathologic controls.” (Ref.11)

Download the SYNTap Test Specification Sheet for details.

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.